Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)
3상
완료
NCT00365859
| 대상 질환 | Autistic Disorder, Behavioral Symptoms |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Otsuka Pharmaceutical Development & Commercialization, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 330 명 |
|---|
| 중재(약물) | Aripiprazole |
|---|
| 시작일 | 2006년 9월 1일 |
|---|
| 완료일 | 2009년 6월 1일 |
|---|
| 결과 공개일 | 2010년 1월 25일 |
|---|
요약
This study will provide long-term safety data for patients who are taking aripiprazole for up to 1 year. Most patients enrolled in this study will have participated in a short-term study with aripiprazole (CN138-178 \[NCT00332241\] or CN138-179 \[NCT00337571\]).
Number of Participants With Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (AEs), Deaths, AEs Leading to Discontinuation, Extra Pyramidal Syndrome (EPS)-Related AEs
From Screening (up to 42 days prior to treatment start) through Week 52 (end of study) for SAEs; from Week 0 (Baseline) through Week 52 (End of Study) for AEs · Participants
| De Novo | 0 Participants |
|---|
| Rollover Placebo | 0 Participants |
|---|
| Rollover Aripiprazole | 0 Participants |
|---|
| Total | 0 Participants |
|---|
| De Novo | 3 Participants |
|---|
| Rollover Placebo | 1 Participants |
|---|
Mean Change From Baseline in Total Simpson-Angus Scale (SAS) At Week 8, Week 26, and Week 52
Baseline, Week 8, Week 26, Week 52 · units on a scale
| De Novo | 10.7 ± 1.40 units on a scale |
|---|
| Rollover Placebo | 10.6 ± 1.17 units on a scale |
|---|
| Rollover Aripiprazole | 11.0 ± 2.11 units on a scale |
|---|
| Total | 10.8 ± 1.77 units on a scale |
|---|
| De Novo | -0.3 ± 1.13 units on a scale |
|---|
| Rollover Placebo | 0.1 ± 1.51 units on a scale |
|---|
Mean Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) At Week 8, Week 26, and Week 52
Baseline, Week 8, Week 26, Week 52 · units on a scale
| De Novo | 0.5 ± 1.90 units on a scale |
|---|
| Rollover Placebo | 0.5 ± 1.02 units on a scale |
|---|
| Rollover Aripiprazole | 0.3 ± 1.23 units on a scale |
|---|
| Total | 0.4 ± 1.40 units on a scale |
|---|
| De Novo | -0.3 ± 1.45 units on a scale |
|---|
| Rollover Placebo | -0.1 ± 0.87 units on a scale |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.